Anti-Mullerian hormone is associated with extrauterine involvement and stage of disease in patients with endometrial cancer
Küçük Resim Yok
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
INFORMA HEALTHCARE
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Our aim was to evaluate serum levels of anti-Mullerian hormone (AMH) and also immunohistochemical (IHC) staining properties of AMH receptor type II (AMHRII) in patients with endometrial cancer (EC) and a control group. Preoperatively, serum levels of AMH were assessed and AMHRII expression was evaluated by immunohistochemistry in a benign and malignant group. AMH serum levels of the control group and EC patients were comparable. For EC patients, there was no difference with respect to the AMH levels and tumour stage; grade; histological type; deep myometrial invasion; lymphovascular space invasion or lymph node involvement. However, AMH levels in patients with extrauterine involvement were higher than patients with disease confined to the uterus. EC samples were more likely to be stained positive for AMHRII than benign lesions. Also, as the stage of the lesion worsens, the rate of IHC staining of AMHRII decreases. In conclusion, AMHRII is expressed in normal endometrial cells as well as endometrial cancer cells. AMH levels increase in EC, with extrauterine involvement at least in locally advanced disease. Also AMH expression decreases as the disease is staged-up.
Açıklama
Anahtar Kelimeler
Anti-Mullerian hormone, anti-Mullerian hormone receptor type II, endometrial cancer, extrauterine involvement, immunohistochemical staining
Kaynak
JOURNAL OF OBSTETRICS AND GYNAECOLOGY
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
35
Sayı
2
